Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $51.13, for a total value of $8,500,362.50. Following the completion of the transaction, the chief executive officer directly owned 8,841,783 shares of the company’s stock, valued at $452,080,364.79. This represents a 1.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Up 10.9%

Shares of NASDAQ:TEM opened at $55.48 on Friday. Tempus AI, Inc. has a 52-week low of $41.73 and a 52-week high of $104.32. The firm has a market capitalization of $9.92 billion, a P/E ratio of -39.35 and a beta of 4.90. The stock has a 50 day moving average price of $50.65 and a 200-day moving average price of $63.58. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Company set its inaugural Investor Day for May 29, 2026 — management will present strategy, product road map and commercialization plans, which can increase visibility and reduce short-term uncertainty around growth targets. Tempus to Host Inaugural Investor Day on May 29, 2026
• Positive Sentiment: Brand and partnership momentum: Tempus was named to TIME’s 10 Most Influential Health & Life Science Companies of 2026 and announced a multi?year collaboration with USC/Keck, boosting the company’s credibility in AI-driven precision medicine and supporting longer-term commercial adoption. Tempus AI’s TIME Honor And USC Deal Test Its Long Term Thesis
• Positive Sentiment: Bull case coverage surfaced (Gannon Capital summary) highlighting long?term upside drivers and growth potential, which may attract momentum buyers and retail interest. Is Tempus AI, Inc. (TEM) A Good Stock To Buy Now?
• Neutral Sentiment: CEO Eric Lefkofsky sold 166,250 shares under a pre?arranged Rule 10b5?1 plan (disclosed filing). Such planned insider sales often serve liquidity/personal reasons but can still be interpreted variably by the market. SEC Form 4 disclosure
• Neutral Sentiment: Analyst/valuation notes show mixed views: small tweak to blended fair value and writeups assessing a short-term bounce versus longer-term declines — suggesting investors are debating whether recent gains are sustainable. How The Tempus AI (TEM) Narrative Is Shifting Around Data, Partnerships And Growth Visibility
• Negative Sentiment: Tempus faces proposed class action litigation related to collection of genetic information in an acquisition — legal exposure and potential remediation costs create downside risk and uncertainty that can pressure sentiment and valuation. Tempus AI Faces Class Action Cases for Collection of Genetic Information in Acquisition
• Negative Sentiment: Peer comparison pieces favor Illumina (ILMN) on valuation and earnings outlook, which could steer institutional allocation away from TEM if investors view ILMN as the better pure?play oncology/ genomics investment. Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC bought a new position in Tempus AI during the 3rd quarter valued at approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in Tempus AI during the 4th quarter valued at $27,000. Harvest Fund Management Co. Ltd purchased a new stake in Tempus AI during the 3rd quarter valued at $38,000. Tsfg LLC boosted its stake in Tempus AI by 1,515.2% during the 3rd quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after purchasing an additional 500 shares during the last quarter. Finally, Cloud Capital Management LLC purchased a new stake in Tempus AI during the 3rd quarter valued at $44,000. Institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TEM. JPMorgan Chase & Co. decreased their target price on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Morgan Stanley reduced their price objective on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Wall Street Zen lowered Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research report on Wednesday, March 11th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.36.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.